As in hematological malignancies, a favorable cytokine profile induced by lymphodepletion appears to be necessary for CAR-T therapy probably because lymphodepleting conditioning eliminates regulatory T cells [139]. ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy was investigated in a phase II study (NCT04044768) in synovial and myxoid liposarcoma patients who had received prior chemotherapy and whose tumors express the MAGE-A4 tumor antigen [39]. The gene discussed is MAGEA4; the disease is hematologic disorder.